Repression of HIP/RPL29 expression induces differentiation in colon cancer cells

J Cell Physiol. 2006 May;207(2):287-92. doi: 10.1002/jcp.20589.

Abstract

We had previously shown that the expression of heparin/heparan sulfate interacting protein/ribosomal protein L29 (HIP/RPL29) was upregulated in colon cancer tissues. The present study investigated the role of HIP/RPL29 in differentiation in colon cancer cells. Inducing cellular differentiation in HT-29 cells by both sodium butyrate and glucose deprivation resulted in a significant downregulation of HIP/RPL29 expression. The beta-catenin/Tcf-4 pathway is the most important pathway controlling the switch between cellular differentiation and proliferation in intestinal epithelial cells. Inducing differentiation by dominant-negative inhibition of the beta-catenin/Tcf-4 complexes in LS174T cells also resulted in downregulation of HIP/RPL29. To determine whether a lower expression of HIP/RPL29 could induce differentiation in cancer cells, small interfering RNA (siRNA) targeting HIP/RPL29 was transfected into LS174T cells. The resultant knockdown of HIP/RPL29 expression induced cellular differentiation, as shown by the increased expression of two known markers of differentiation in LS174T cells, galectin-4 and mucin-2. In addition, the differentiation process induced by repression of HIP/RPL29 expression was accompanied by the upregulation of p21 and p53. In conclusion, HIP/RPL29 plays a role in the cellular differentiation process in colon cancer cells. The differentiation process is at least partially mediated by the upregulation of p21 and p53 pathways.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaline Phosphatase / metabolism
  • Blood Coagulation Factors / genetics
  • Blood Coagulation Factors / metabolism
  • Blood Coagulation Factors / physiology*
  • Butyrates / pharmacology
  • Cell Differentiation / drug effects
  • Cell Differentiation / physiology*
  • Cell Line, Tumor
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / physiopathology
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Galectin 4 / metabolism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Glucose / deficiency
  • HCT116 Cells
  • HT29 Cells
  • Humans
  • Mucin-2
  • Mucins / metabolism
  • RNA, Small Interfering / genetics
  • RNA-Binding Proteins
  • Ribosomal Proteins
  • Signal Transduction / physiology
  • TCF Transcription Factors / genetics
  • Transcription Factor 7-Like 2 Protein
  • Tumor Suppressor Protein p53 / metabolism
  • beta Catenin / antagonists & inhibitors

Substances

  • Blood Coagulation Factors
  • Butyrates
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Galectin 4
  • MUC2 protein, human
  • Mucin-2
  • Mucins
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • RPL29 protein, human
  • Ribosomal Proteins
  • TCF Transcription Factors
  • TCF7L2 protein, human
  • Transcription Factor 7-Like 2 Protein
  • Tumor Suppressor Protein p53
  • beta Catenin
  • Alkaline Phosphatase
  • Glucose